Pharmaceutical manufacturer for Erythromycin

Catalent is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad, deep-scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred Contract Development and Manufacturing Organization (CDMO) partner for personalized medicines, blockbuster drugs and consumer health brand extensions. Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply over 80 billion doses of nearly 8,000 products annually. Its rapidly growing expert workforce exceeds 18,000, including more than 3,000 scientists and technicians. Headquartered in Somerset, New Jersey, Catalent, Inc. (NYSE:CTLT), is in S&P 500® company, and generated nearly $5 billion in revenue in its 2022 fiscal year.

Alembic Pharmaceuticals Limited is involved in manufacturing and marketing India Formulations, International Generics, and Active Pharmaceutical Ingredients with vertical integration capabilities. Headquartered in Vadodara, Gujarat, we derive a third of our revenue of over $600 million from the India market.

Greetings, we are Sandoz B2B. As a division of Sandoz, we are completely dedicated to ensuring availability of cost-effective medication for everyone. We distribute high-quality medication globally through close collaboration with pharmaceutical partners. Whether it involves active pharmaceutical ingredients, finished dosage products, or comprehensive end-to-end CDMO solutions, we are here for you.

HEC Pharm Co has obtained approval from the FDA and EDQM as a pharmaceutical manufacturer of both active pharmaceutical ingredients (API) and dosage forms. Presently, HEC is the largest global producer of Macrolides API, including Erythromycin and its derivatives. Sunshine Lake Pharma Co, a subsidiary of HEC Pharm, was established to supply finished pharmaceuticals (dosage forms) to the markets of the United States and European Union (EU).

Zim offers innovative solutions for administering medications, focusing on enhancing patient convenience and compliance. The company utilizes its own advanced technologies, such as modified release and taste masking, to create and produce distinct pharmaceutical products. Their range includes oral solid dosage formulations and pre-formulations (PFI), encompassing tablets, capsules, dry syrups, pellets, granules, and orally disintegrating strips (ODS). Additionally, they provide services for site transfer/variation for sustained release tablets, oral disintegrating tablets, fast disintegrating capsules, and more.

AbbVie Contract Manufacturing boasts more than three decades of expertise in AbbVie's manufacturing sector. Operating as an integrated CMO, it harnesses extensive knowledge, cooperation, and state-of-the-art facilities, delivering comprehensive services to customers across various domains such as development, production, compliance, and marketing, while ensuring adherence to the highest international benchmarks. Additionally, AbbVie Contract Manufacturing aids clients in streamlining manufacturing, optimizing supply networks, expediting time-to-market, ensuring adherence to regulations, and providing unparalleled quality.

STERIS Applied Sterilization Technologies offers sterilization services, laboratory testing, and product and packaging testing to companies in the medical device and pharmaceutical industries.

Anuh Pharma Ltd., a Bulk Drugs Manufacturing Company is part of the INR 8.5 bn SK Group of Companies, which employs 2000+ people across businesses such as Manufacturing of API's, Pharma Formulations, Distribution and Logistics. Established in 1960, Anuh Pharma Ltd. today is one of the largest manufacturers of Macrolides and Anti-TB products in India, besides being a major player in Anti-Bacterials, Anti-Malarial, and Corticosteroids.

Mehta API Pvt Ltd is involved in the production and promotion of APIs & Advanced Drug Intermediates on a global scale. Mehta Api takes great pride in its accomplishments since its establishment. Our journey is marked by numerous success stories, many of which have been unprecedented in the pharmaceutical industry. Our achievements are attested by our utmost priorities - Product Excellence and Customer service. We firmly believe that sustained business success is based on values. Upholding business ethics is essential as they function as a long-term insurance policy. We are dedicated to achieving Excellence in Product Quality and maintaining strict delivery schedules.

Established in the year 1991, SM Biomed Sdn. Bhd. is a leading manufacturer of Active Pharmaceutical Ingredients (APIs) and Intermediates based out in Malaysia With our state-of-the-art manufacturing facility certified by USFDA, EDQM, EUGMP and NPRA (Malaysia), we are dedicated to improve the quality of life through developing and delivering innovative solutions and products at an affordable cost. With a legacy spanning more than three decades and pioneers for Macrolide based antibiotics, we work with customers globally with speed, efficiency and cost effective manufacturing capabilities. SM Biomed has grown as a market leader in Macrolides antibiotics and evolved into a knowledge driven company providing reliable pharmaceutical services including developing and manufacturing APIs and Intermediates. From pipeline to production, we make innovative, quality driven and customised products more accessible. We are a quality driven and R&D focused API manufacturing company with a diverse product portfolio catering various therapeutic segments.

CALYX is an Active Pharmaceutical Ingredient and Intermediate manufacturer successfully inspected by the regulatory agencies of USFDA, EDQM, WHO Geneva and other accreditations for the manufacturing site located at Tarapur, Maharashtra (India).

Founded in October 2000, Zhejiang Guobang Pharmaceutical is a core enterprise of the Guobang Pharmaceutical Group. The company is located in the Hangzhou Bay Shangyu Economic and Technological Development Zone in Shangyu District, Shaoxing, Zhejiang Province, lying between the provincial capital of Hangzhou and the coastal city of Ningbo, in the hinterlands of the Yangtze River Delta economic region. It is well-connected to the transport network, with two sea bridges leading straight to Shanghai, as well as easy access to an airport, the high-speed rail, expressways, national highways, canals and ports. The company's core is in pharmaceutical manufacturing technology and it is engaged in the R&D, production, and operation for pharmaceutical and veterinary APIs and is a well-established manufacturer of synthetic APIs in China. The company's primary products are quinolones and macrolides and it is the world's leading producer of azithromycin, clarithromycin, roxithromycin, ciprofloxacin, enrofloxacin and marbofloxacin. Its production capacity and market share are above 35% in both the Chinese and international markets and its products are exported to 112 countries and regions, covering 6.5 billion people. Its sales network covers all regions of China and the US and European markets. The company is a national high-tech enterprise, with a national-level postdoctoral research station, a province-level pharmaceutical research institute, and a province-level enterprise technology center. It has received National Production Safety Standardization Certification, ISO 9001：2008 quality management certification and ISO 14001 environmental management system certification. All products have received national pharmaceutical and veterinary GMP certification, and all main products have received EUGMP, FDA, PMDA, ANVISA, MFDS and other certifications.

Ercros is an industrial group diversified into three business areas: the Chlorine Derivatives Division, a strategic unit whose common nexus is chlorine; the Intermediate Chemicals Division, focused on formaldehyde chemistry; and the Pharmaceuticals Division, dedicated to pharmaceutical active ingredients. It is a leading company in the main markets in which it operates for most of its products.

elm-plastic GmbH is a German family-owned business that was established in 1969. Operating on a production area of 4500 square meters, we manufacture high-quality plastic components to a technically advanced standard with a workforce of approximately 120 employees working in three shifts. Our product line primarily comprises of packaging products for pharmaceuticals and dosing instruments for both human and veterinary medicine. Our satisfied customer base includes renowned international pharmacists and bottlers. These products are the result of longstanding collaboration between pharmacists, bottlers, users, and our development department.

For the past four decades, Kaneka has been producing advanced intermediates for the pharmaceutical industry using its unique combination of bio-transformations and organic synthesis. As a research-driven manufacturer, Kaneka supplies valuable chiral synthons to its customers worldwide through innovative and cost-effective processes. With its intensive R&D activities, Kaneka provides global support to its customers.

Established in 1968, Fermic has grown to become one of the leading fermentation companies in Latin America. Accredited by the US FDA, Fermic specializes in the manufacturing of fermentation products such as APIs, with potassium clavulanate as its flagship product available in oral and sterile formulations. Additionally, Fermic offers contract manufacturing services for fermentation products including Active Pharmaceutical Ingredients and Enzymes.

TZF Polfa SA, is among the most seasoned pharmaceutical firms globally, with a heritage tracing back to 1823. Our primary aim is to enhance the well-being of our clientele. Consequently, we strive to create top-notch products and services from the perspective of the patients. We ensure that these products are accessible to those in need. Polfa Tarchomin is a frontrunner in the anti-infectives market and also commands a substantial market share in insulin, psychotropic drugs, and dermatology.

ANGUS Life Sciences is a premier global provider of essential raw materials for pharmaceutical and biopharmaceutical production. From economical foundational elements and versatile topical excipients to top-quality TRIS reagents, we deliver the utmost purity and most uniform resources to the industry. Our commitment to a dependable, fully traceable supply is unparalleled, and exclusively offered by ANGUS, the sole fully integrated producer of TRIS reagents in the world. From initial exploration to product launch, Explore A Superior Approach™ with ANGUS.